Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.45 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512958 | 0.93 | PARP1 (0.52) | PARP1CHEK1PIM1RPS6KA3MAOA | |
| SCHEMBL4508399 | 0.84 | PARP1 (0.48) | PARP1CHEK1PIM1RPS6KA3MAOA | |
| SCHEMBL4875349 | 0.82 | PARP1 (0.51) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL5565888 | 0.82 | PARP1 (0.55) | PARP1CHEK1PIM1RPS6KA3MAOA | |
| SCHEMBL1346000 | 0.82 | PARP1 (0.51) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL4503343 | 0.82 | PARP1 (0.49) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL3489621 | 0.81 | PARP1 (0.50) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL4876430 | 0.81 | PARP1 (0.53) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL8814884 | 0.81 | KDM4E (0.49) | MAOAALDH1A1LSSFGFR1SRC | |
| SCHEMBL4497910 | 0.79 | PARP1 (0.51) | PARP1CHEK1PIM1RPS6KA3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | claimed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| US-12012400-B2 | Method of the preparation of fused multicyclic compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-06-18 | — | — | US | disclosed |
| US-20230265088-A1 | The Method of the Preparation of Fused Multicyclic Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-08-24 | — | — | US | disclosed |
| US-20230265088-A1 | The Method of the Preparation of Fused Multicyclic Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-08-24 | — | — | US | disclosed |
| US-20230265088-A1 | The Method of the Preparation of Fused Multicyclic Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-08-24 | — | — | US | disclosed |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| EP-1458394-B1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265088-A1 | The Method of the Preparation of Fused Multicyclic Compounds | CYP2W1, CYP1B1, CYP2F1 | PARP1 339/4885CHEK1 3394/4885PIM1 2582/4885 |
| US-12012400-B2 | Method of the preparation of fused multicyclic compounds | CYP1B1, CYP2W1, CYP2F1 | PARP1 312/4885CHEK1 3459/4885PIM1 2502/4885 |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | GSK3A, GSK3B, PYGB | PARP1 2215/4885CHEK1 881/4885PIM1 1748/4885 |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | GSK3A, GSK3B, PSEN1 | PARP1 2627/4885CHEK1 1014/4885PIM1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.